Shared decision-making about GLP-1 RAs use with women with PCOS should consider the lack of long-term safety data, the potential side effects, and the likelihood of requiring long-term therapy due to the high risk of weight regain after discontinuation. The gene discussed is GCG; the disease is polycystic ovary syndrome.